Literature DB >> 6796771

Hypoxanthine-guanine phosphoribosyltransferase variants: correlation of clinical phenotype with enzyme activity.

T Page, B Bakay, E Nissinen, W L Nyhan.   

Abstract

A deficiency of the enzyme hypoxanthine-guanine phosphoribosyltransferase(HGPRT) is associated with a varying clinical picture which may include hyperuricaemia, neurological abnormalities and bizarre self-mutilating behaviour. Due to technical problems with the usual in vitro enzyme assays, it has not been possible to establish a correlation between the degree of the enzyme deficiency and the severity of the clinical manifestations. In this study, the HGPRT activity of 12 patients with various clinical features was measured by quantitative analysis of the incorporation of radioactive precursors into purine compounds in intact fibroblasts. The results demonstrate that a correlation between the severity of the clinical symptoms and the degree of the enzyme deficiency as measured in intact fibroblasts does in fact exist.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796771     DOI: 10.1007/BF02263652

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  14 in total

1.  Measurement of free nucleotides in cultured human lymphoid cells using high pressure liquid chromatography.

Authors:  D P Brenton; K H Astrin; M K Cruikshank; J E Seegmiller
Journal:  Biochem Med       Date:  1977-06

2.  Hypoxanthine phosphoribosyltransferase activity in intact fibroblasts from patients with X-linked hyperuricemia.

Authors:  M J Holland; A M DiLorenzo; J Dancis; M E Balis; T F Yü; R P Cox
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

3.  Purine nucleotide metabolism and nucleotide pool sizes in synchronized lymphoma L5178Y cells.

Authors:  F F Snyder; J F Henderson; S C Kim; A R Paterson; L W Brox
Journal:  Cancer Res       Date:  1973-10       Impact factor: 12.701

4.  A specific enzyme defect in gout associated with overproduction of uric acid.

Authors:  W N Kelley; F M Rosenbloom; J F Henderson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1967-06       Impact factor: 11.205

5.  The spectrum of hypoxanthine-guanine phosphoribosyltransferase deficiency.

Authors:  B T Emmerson; L Thompson
Journal:  Q J Med       Date:  1973-04

6.  Kinetic studies of hypoxanthine-guanine phosphoribosyltransferase.

Authors:  J F Henderson; L W Brox; W N Kelley; F M Rosenbloom; J E Seegmiller
Journal:  J Biol Chem       Date:  1968-05-25       Impact factor: 5.157

7.  Analysis of radioactive and nonradioactive purine bases, nucleosides, and nucleotides by high-speed chromatography on a single column.

Authors:  B Bakay; E Nissinen; L Sweetman
Journal:  Anal Biochem       Date:  1978-05       Impact factor: 3.365

8.  Hypoxanthine-guanine phosphoribosyltransferase: characteristics of the mutant enzyme in erythrocytes from patients with the Lesch-Nyhan syndrome.

Authors:  W J Arnold; J C Meade; W N Kelley
Journal:  J Clin Invest       Date:  1972-07       Impact factor: 14.808

9.  Utilization of purines by an HPRT variant in an intelligent, nonmutilative patient with features of the Lesch-Nyhan syndrome.

Authors:  B Bakay; E Nissinen; L Sweetman; U Francke; W L Nyhan
Journal:  Pediatr Res       Date:  1979-12       Impact factor: 3.756

10.  A distinct human variant of hypoxanthine-guanine phosphoribosyl transferase.

Authors:  L Sweetman; M A Hoch; B Bakay; M Borden; P Lesh; W L Nyhan
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

View more
  36 in total

1.  Clinical utility gene card for: Lesch-Nyhan syndrome.

Authors:  Rosa J Torres; Juan G Puig; Irène Ceballos-Picot
Journal:  Eur J Hum Genet       Date:  2010-07-21       Impact factor: 4.246

2.  Developmental disorder associated with increased cellular nucleotidase activity.

Authors:  T Page; A Yu; J Fontanesi; W L Nyhan
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-14       Impact factor: 11.205

3.  Real-time PCR and linkage studies to identify carriers presenting HPRT deleted gene.

Authors:  Cristina Lapucci; Diego Pomarè Montin; Massimo Pandolfo; Matteo Bertelli
Journal:  Mol Med       Date:  2006 Sep-Oct       Impact factor: 6.354

4.  Family studies of the Lesch-Nyhan syndrome: the use of a restriction fragment length polymorphism (RFLP) closely linked to the disease gene for carrier state and prenatal diagnosis.

Authors:  D A Gibbs; C M Headhouse-Benson; R W Watts
Journal:  J Inherit Metab Dis       Date:  1986       Impact factor: 4.982

5.  Do clinical features of Lesch-Nyhan disease correlate more closely with hypoxanthine or guanine recycling?

Authors:  David J Schretlen; Wynne Callon; Rebecca E Ward; Rong Fu; Tiffany Ho; Barry Gordon; James C Harris; H A Jinnah
Journal:  J Inherit Metab Dis       Date:  2015-06-12       Impact factor: 4.982

6.  Reduced urinary serotonin excretion after intake of high doses of hypoxanthine.

Authors:  H Manzke; H Gustmann
Journal:  Eur J Pediatr       Date:  1989-01       Impact factor: 3.183

Review 7.  Clinical and biochemical aspects of uric acid overproduction.

Authors:  J García Puig; F A Mateos
Journal:  Pharm World Sci       Date:  1994-04-15

8.  Clinical severity in Lesch-Nyhan disease: the role of residual enzyme and compensatory pathways.

Authors:  Rong Fu; Diane Sutcliffe; Hong Zhao; Xinyi Huang; David J Schretlen; Steve Benkovic; H A Jinnah
Journal:  Mol Genet Metab       Date:  2014-11-08       Impact factor: 4.797

Review 9.  Genotypic and phenotypic spectrum in attenuated variants of Lesch-Nyhan disease.

Authors:  Rong Fu; Chung-Jen Chen; H A Jinnah
Journal:  Mol Genet Metab       Date:  2014-05-28       Impact factor: 4.797

Review 10.  Attenuated variants of Lesch-Nyhan disease.

Authors:  H A Jinnah; Irene Ceballos-Picot; Rosa J Torres; Jasper E Visser; David J Schretlen; Alfonso Verdu; Laura E Laróvere; Chung-Jen Chen; Antonello Cossu; Chien-Hui Wu; Radhika Sampat; Shun-Jen Chang; Raquel Dodelson de Kremer; William Nyhan; James C Harris; Stephen G Reich; Juan G Puig
Journal:  Brain       Date:  2010-02-22       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.